Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | Mkt Perform | JMP Securities | |
| 1/23/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 3/16/2022 | $40.00 | Outperform | SMBC Nikko |
| 3/2/2022 | $53.00 → $40.00 | Market Outperform | JMP Securities |
| 11/10/2021 | $44.00 → $53.00 | Outperform | Credit Suisse |
| 11/2/2021 | $46.00 → $53.00 | Market Outperform | JMP Securities |
| 9/21/2021 | $46.00 | Market Outperform | JMP Securities |
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx Biosciences business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research.
SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT
JMP Securities initiated coverage of Inhibrx Biosciences with a rating of Mkt Perform
JMP Securities downgraded Inhibrx from Mkt Outperform to Mkt Perform
SMBC Nikko initiated coverage of Inhibrx with a rating of Outperform and set a new price target of $40.00
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
424B3 - Inhibrx Biosciences, Inc. (0002007919) (Filer)
8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
SC 13G - Inhibrx Biosciences, Inc. (0002007919) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SC 13G/A - Inhibrx, Inc. (0001739614) (Subject)
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulatory Affairs; and Jack Tsai, M.D., M.B.A., as Vice President of Business Development. "The additions of David, David and Jack come at an important time for Inhibrx, as our pipeline demonstrates meaningful clinical activity in areas of high unmet medical need such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma. We are building a seasoned, world-
JMP Securities analyst Reni Benjamin initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Market Perform rating.
– SEC Filing
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Inhibrx Biosciences, Inc. (NASDAQ:INBX) On May 24, Inhibrx stockholders approved sale of INBRX-101 to Sanofi. The company's s
SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), there is potential to pursue an accelerated approval in the U.S. for INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint. Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients teste
Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events.Topline data from the multiple ascending dose cohorts of 40, 80 and 120 mg/kg demonstrated the average level ("Cavg") of functional alpha-1 antitrypsin ("AAT") achieved by INBRX-101 was 40.4 micromolar ("µM") over the 21-day dosing interval following the third 80 mg/kg dose. Functional AAT levels collected from 65 healthy individuals with the MM genotype revealed a 5th/95th percentile range of 23 to 57 µM and a median of 38 µM.SAN DIEGO, May 16, 2022 /PRNewswire/ -- Inhibrx Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in de
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety and pharmacokinetics of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency, or AATD. Interim functional PK data from this multi-country multi-center Phase 1 study are from 21 patients with AATD, all with the ZZ mutation of the SERPINA1 gene, the underlying caus